Literature DB >> 24947351

Fractalkine (CX3CL1) is involved in the early activation of hypothalamic inflammation in experimental obesity.

Joseane Morari1, Gabriel F Anhe2, Lucas F Nascimento1, Rodrigo F de Moura1, Daniela Razolli1, Carina Solon1, Dioze Guadagnini3, Gabriela Souza1, Alexandre H Mattos4, Natalia Tobar5, Celso D Ramos5, Vinicius D Pascoal4, Mario J Saad3, Iscia Lopes-Cendes4, Juliana C Moraes1, Licio A Velloso6.   

Abstract

Hypothalamic inflammation is a common feature of experimental obesity. Dietary fats are important triggers of this process, inducing the activation of toll-like receptor-4 (TLR4) signaling and endoplasmic reticulum stress. Microglia cells, which are the cellular components of the innate immune system in the brain, are expected to play a role in the early activation of diet-induced hypothalamic inflammation. Here, we use bone marrow transplants to generate mice chimeras that express a functional TLR4 in the entire body except in bone marrow-derived cells or only in bone marrow-derived cells. We show that a functional TLR4 in bone marrow-derived cells is required for the complete expression of the diet-induced obese phenotype and for the perpetuation of inflammation in the hypothalamus. In an obesity-prone mouse strain, the chemokine CX3CL1 (fractalkine) is rapidly induced in the neurons of the hypothalamus after the introduction of a high-fat diet. The inhibition of hypothalamic fractalkine reduces diet-induced hypothalamic inflammation and the recruitment of bone marrow-derived monocytic cells to the hypothalamus; in addition, this inhibition reduces obesity and protects against diet-induced glucose intolerance. Thus, fractalkine is an important player in the early induction of diet-induced hypothalamic inflammation, and its inhibition impairs the induction of the obese and glucose intolerance phenotypes.
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24947351     DOI: 10.2337/db13-1495

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  53 in total

Review 1.  Hypothalamic inflammation in obesity and metabolic disease.

Authors:  Alexander Jais; Jens C Brüning
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

Review 2.  Glia: silent partners in energy homeostasis and obesity pathogenesis.

Authors:  John D Douglass; Mauricio D Dorfman; Joshua P Thaler
Journal:  Diabetologia       Date:  2016-12-16       Impact factor: 10.122

Review 3.  Hypothalamic innate immune reaction in obesity.

Authors:  Stefanie Kälin; Frank L Heppner; Ingo Bechmann; Marco Prinz; Matthias H Tschöp; Chun-Xia Yi
Journal:  Nat Rev Endocrinol       Date:  2015-03-31       Impact factor: 43.330

4.  "Insulin-like" effects of palmitate compromise insulin signalling in hypothalamic neurons.

Authors:  Martin Benzler; Jonas Benzler; Sigrid Stoehr; Cindy Hempp; Mohammed Z Rizwan; Phil Heyward; Alexander Tups
Journal:  J Comp Physiol B       Date:  2019-05-23       Impact factor: 2.200

5.  Hypothalamic stearoyl-CoA desaturase-2 (SCD2) controls whole-body energy expenditure.

Authors:  R F de Moura; L F Nascimento; L M Ignacio-Souza; J Morari; D S Razolli; C Solon; G F P de Souza; W T Festuccia; L A Velloso
Journal:  Int J Obes (Lond)       Date:  2015-09-22       Impact factor: 5.095

6.  Sex differences in motivational responses to dietary fat in Syrian hamsters.

Authors:  John L Shannonhouse; Danielle M Grater; Daniel York; Paul J Wellman; Caurnel Morgan
Journal:  Physiol Behav       Date:  2015-04-18

7.  Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy.

Authors:  Keehoon Jung; Takahiro Heishi; Omar F Khan; Piotr S Kowalski; Joao Incio; Nuh N Rahbari; Euiheon Chung; Jeffrey W Clark; Christopher G Willett; Andrew D Luster; Seok Hyun Yun; Robert Langer; Daniel G Anderson; Timothy P Padera; Rakesh K Jain; Dai Fukumura
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

Review 8.  The melanocortin pathway and control of appetite-progress and therapeutic implications.

Authors:  Giulia Baldini; Kevin D Phelan
Journal:  J Endocrinol       Date:  2019-04-01       Impact factor: 4.286

9.  Magnetic resonance assessment of the cerebral alterations associated with obesity development.

Authors:  Blanca Lizarbe; Basilio Campillo; Irene Guadilla; Pilar López-Larrubia; Sebastián Cerdán
Journal:  J Cereb Blood Flow Metab       Date:  2020-07-23       Impact factor: 6.200

Review 10.  Obesity, Neuroinflammation, and Reproductive Function.

Authors:  Nancy M Lainez; Djurdjica Coss
Journal:  Endocrinology       Date:  2019-11-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.